MYC and diffuse large B-cell lymphoma: Nevertheless, ibrutinib with R-CHOP did not benefit the overall patients with untreated non-GCB DLBCL in a randomized, placebo-controlled, phase III PHEONIX study [6], but addition of ibrutinib to R-CHOP benefited younger patients of DLBCL, especially those with both c-MYC and BCL-2 overexpression.